KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Shares Outstanding (Weighted Average) (2018 - 2025)

Historic Shares Outstanding (Weighted Average) for Aurinia Pharmaceuticals (AUPH) over the last 6 years, with Q3 2025 value amounting to $135.2 million.

  • Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) fell 571.32% to $135.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.2 million, marking a year-over-year decrease of 571.32%. This contributed to the annual value of $143.1 million for FY2024, which is 12.5% down from last year.
  • Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $135.2 million in Q3 2025, which was down 571.32% from $136.9 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $144.0 million for Q1 2024, and its period low was $127.4 million during Q1 2021.
  • For the 5-year period, Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $138.8 million, with its median value being $141.9 million (2022).
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) soared by 1120.4% in 2022 and then tumbled by 571.32% in 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $129.4 million in 2021, then grew by 9.7% to $141.9 million in 2022, then grew by 0.93% to $143.2 million in 2023, then fell by 0.12% to $143.1 million in 2024, then dropped by 5.52% to $135.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $135.2 million for Q3 2025, versus $136.9 million for Q2 2025 and $138.9 million for Q1 2025.